Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 10,713 shares of the business's stock in a transaction on Monday, May 6th. The stock was acquired at an average price of $13.62 per share, with a total value of $145,911.06. Following the transaction, the insider now directly owns 3,079,443 shares of the company's stock, valued at approximately $41,942,013.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Thursday, May 2nd, Saba Capital Management, L.P. purchased 26,274 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average cost of $13.46 per share, for a total transaction of $353,648.04.
- On Tuesday, April 30th, Saba Capital Management, L.P. acquired 16,573 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $13.13 per share, with a total value of $217,603.49.
- On Friday, April 26th, Saba Capital Management, L.P. bought 120,304 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average price of $13.00 per share, for a total transaction of $1,563,952.00.
- On Wednesday, April 24th, Saba Capital Management, L.P. purchased 20,529 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average price of $13.12 per share, with a total value of $269,340.48.
- On Monday, April 22nd, Saba Capital Management, L.P. purchased 2,022 shares of Abrdn Life Sciences Investors stock. The stock was purchased at an average price of $12.88 per share, for a total transaction of $26,043.36.
- On Thursday, April 18th, Saba Capital Management, L.P. acquired 81,738 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average cost of $12.80 per share, with a total value of $1,046,246.40.
Abrdn Life Sciences Investors Price Performance
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
Abrdn Life Sciences Investors stock opened at $13.74 on Wednesday. Abrdn Life Sciences Investors has a fifty-two week low of $11.34 and a fifty-two week high of $14.37. The stock's fifty day moving average is $13.40 and its two-hundred day moving average is $13.18.
Abrdn Life Sciences Investors Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were issued a dividend of $0.39 per share. This is an increase from Abrdn Life Sciences Investors's previous quarterly dividend of $0.30. This represents a $1.56 annualized dividend and a yield of 11.35%. The ex-dividend date was Wednesday, February 21st.
Hedge Funds Weigh In On Abrdn Life Sciences Investors
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. increased its stake in shares of Abrdn Life Sciences Investors by 4.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 18,414 shares of the company's stock worth $251,000 after purchasing an additional 814 shares in the last quarter. Kingsview Wealth Management LLC raised its holdings in shares of Abrdn Life Sciences Investors by 2.5% in the fourth quarter. Kingsview Wealth Management LLC now owns 36,937 shares of the company's stock worth $497,000 after acquiring an additional 904 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Abrdn Life Sciences Investors by 1.7% in the third quarter. Janney Montgomery Scott LLC now owns 72,249 shares of the company's stock valued at $901,000 after acquiring an additional 1,220 shares in the last quarter. Shaker Financial Services LLC boosted its stake in shares of Abrdn Life Sciences Investors by 2.1% during the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company's stock valued at $830,000 after acquiring an additional 1,342 shares during the last quarter. Finally, Future Financial Wealth Managment LLC purchased a new stake in Abrdn Life Sciences Investors during the 1st quarter worth about $27,000. Institutional investors and hedge funds own 32.21% of the company's stock.
About Abrdn Life Sciences Investors
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
